Phagenyx
Generated by Meeveem AI
"Restoring swallowing control through brain stimulation for stroke recovery patients"
Manchester
•51 - 250 Employees
•Medical Devices
About Phagenyx
Phagenesis develops the Phagenyx System, a medical device that treats neurogenic dysphagia in stroke patients through pharyngeal electrical stimulation. The technology restores the brain's ability to control swallowing, enabling faster, safer recovery. Clinical trials show it reduces time to oral nutrition by 58%, shortens hospital stays by 37%, and significantly lowers aspiration risk. The company serves healthcare providers in acute care facilities across the United States and Europe. Founded in 2007 to commercialise University of Manchester research, Phagenesis addresses a critical need where nearly half of stroke patients experience persistent swallowing difficulty, leading to serious complications and increased mortality.
65
Team Members
2007
Founded
Medical Devices
Sector
Hybrid
Work Environment
Our Vision
A world where stroke survivors recover swallowing function rapidly through brain-based therapies, where dysphagia no longer leads to preventable complications, and healthcare systems deliver faster, evidence-backed interventions.
Our Mission
At Phagenesis, our mission is to transform the treatment of neurogenic dysphagia worldwide by restoring the brain-to-swallow connection, improving recovery, and reducing the burden of care for patients, families, and healthcare systems.